Today: 14 June 2026
Browse Category

NASDAQ:ERNA 29 October 2025 - 12 May 2026

Ernexa Stock’s 58% Jump Shows How Fast a Tiny Biotech Can Reprice on Ovarian-Cancer Hopes

Ernexa Stock’s 58% Jump Shows How Fast a Tiny Biotech Can Reprice on Ovarian-Cancer Hopes

Ernexa Therapeutics shares jumped 58.5% to $11.43 Tuesday after renewed investor focus on its preclinical ovarian-cancer therapy ERNA-101, following a May 11 investor event. Trading volume reached about 18.85 million shares. The company reported $8.3 million in cash as of April 30, less than needed for its 12-month plan, and may use an at-the-market stock sale to raise funds.
12 May 2026
··
Why Ernexa Therapeutics Stock Jumped After ERNA-101 Ovarian Cancer Survival Data

Why Ernexa Therapeutics Stock Jumped After ERNA-101 Ovarian Cancer Survival Data

Ernexa Therapeutics said its ERNA-101 cell therapy plus PD-1 blockade cleared tumors and achieved 100% long-term survival in preclinical ovarian cancer models. Shares jumped about 60% after the announcement, trading between $3.70 and $7.66. The company remains preclinical and recently completed a 1-for-25 reverse stock split to maintain its Nasdaq listing.
6 May 2026
···
Ernexa Therapeutics (ERNA) Skyrockets on Cancer Therapy Deal – Will Rally Last?

Ernexa Therapeutics (ERNA) Skyrockets on Cancer Therapy Deal – Will Rally Last?

Ernexa Therapeutics shares jumped nearly 50% to $1.80 intraday on October 29, 2025, after announcing a manufacturing partnership with Cellipont Bioservices to advance its ovarian cancer cell therapy, ERNA-101, toward clinical trials. Trading volume surged. Despite the rally, ERNA stock remains down about 58% in 2025 and 89% year-on-year after previous setbacks and a reverse stock split.
29 October 2025
··

Stock Market Today

  • Caledonia Mining Shares Decline Despite Strong Motapa Drill Results, Analysts See Undervaluation at $42.73
    June 14, 2026, 12:32 AM EDT. Caledonia Mining (NYSEAM:CMCL) shares have fallen about 23% year to date despite high-grade gold drill results from its Motapa project in Zimbabwe, with intercepts up to nearly 14g/t over 19 metres. Analysts value the stock at a fair price of $42.73, more than double the last close of $20.18, citing growth potential from new assets like the Bilboes project. The 5-year shareholder return remains strong at approximately 104%. Risks include Zimbabwe-specific challenges and reliance on the Blanket Mine. The stock currently shows a value score of 6 and an intrinsic discount of 24%, suggesting possible mispricing. Investors are advised to weigh risks against long-term growth prospects before deciding.

Latest articles

Kraft Heinz Shares Rally for Six Days—Is KHC a Buy Now?

Kraft Heinz Shares Rally for Six Days—Is KHC a Buy Now?

14 June 2026
Kraft Heinz closed up 0.70% at $24.39, outpacing the S&P 500, as investors weighed its 6.6% dividend yield against falling organic sales, lower adjusted earnings, and cautious analyst targets; the next earnings update is seen as the key test for whether $600 million in marketing and R&D can revive growth and support the stock’s rebound.
Go toTop